One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients

European Journal of Cancer

Volumn 47, Issue 10, 2011, Pages 1521-1526

  Kawashima, Atsunari ^a   Takayama, Hitoshi ^a   Arai, Yasuyuki ^b   Tanigawa, Go ^c   Nin, Mikio ^d   Kajikawa, Jiro ^e   Imazu, Tetsuo ^f   Kinoshita, Tatsuya ^g   Yasunaga, Yutaka ^h   Inoue, Hitoshi ⁱ   Nishimura, Kenji ^j   Takada, Shingo ^k   Nishimura, Kazuo ^b   Tsujimura, Akira ^a   Nonomura, Norio ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c OSAKA GENERAL MEDICAL CENTER   (Japan)

^d OSAKA ROSAI HOSPITAL   (Japan)

^e SAKAI MUNICIPAL HOSPITAL   (Japan)

^f TOYONAKA MUNICIPAL HOSPITAL   (Japan)

^g SUMITOMO HOSPITAL   (Japan)

^h OSAKA NATIONAL HOSPITAL   (Japan)

ⁱ Ikeda Municipal Hospital   (Japan)

^j Hyogo Prefectural Nishinomiya Hospital   (Japan)

^k OSAKA POLICE HOSPITAL   (Japan)

more..

Author keywords

First line refractory; Progression free survival; Relative dose intensity; Renal cell carcinoma; Sorafenib

Indexed keywords

COLLAGEN TYPE 1; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL FEATURE; DOSE RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JAPANESE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; JAPAN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PYRIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79958865082     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.04.001     Document Type: Article

References (16)

1. H.T. Cohen, and F.J. McGovern Renal-cell carcinoma N Engl J Med 23 2005 2477 2490 (Pubitemid 41770167)
2. S.C. Campbell, R.C. Flanigan, and J.L. Clark Nephrectomy in metastatic renal cell carcinoma Curr Treat Options Oncol 4 2003 363 372
3. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134 (Pubitemid 46089673)
4. H. Akaza, T. Tsukamoto, M. Murai, K. Nakajima, and S. Naito Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma Jpn J Clin Oncol 37 2007 755 762 (Pubitemid 350120299)
5. T. Ueda, Y. Imamura, and A. Komaru Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients Int J Urol 17 2010 811 815
6. R. Epelbaum, N. Haim, M. Ben-Shahar, Y. Ron, and Y. Cohen Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma Isr J Med Sci 24 1988 533 538 (Pubitemid 19052765)
7. D.W. Blayney, M.L. LeBlanc, and T. Grogan Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349) J Clin Oncol 21 2003 2466 2473 (Pubitemid 46606326)
8. R.J. Motzer, J. Bacik, and L.H. Schwartz Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma J Clin Oncol 22 2004 454 463 (Pubitemid 41079774)
9. F.L. Greene, D.L. Page, and I.D. Fleming AJCC Cancer Staging Manual 6th Edn. 2002 Springer-Verlag New York
10. M. Pfreundschuh, L. Trümper, and M. Kloess Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with agressive lymphomas: results of the NHL-B2 trial of the DSHNHL Blood 104 2004 634 641 (Pubitemid 38970554)
11. T. Hirakawa, H. Yamaguchi, and N. Yokose Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma Ann Hematol 89 2010 897 904
12. T.E. Hutson, J. Bellmunt, and C. Porta Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET Eur J Cancer 46 2010 2432 2440
13. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
14. C. Peña, C. Lathia, M. Shan, B. Escudier, and R.M. Bulowski Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial Clin Cancer Res 16 2010 4853 4863
15. E. Jonasch, P. Corn, and L.C. Pagliaro Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma Cancer 116 2010 57 65
16. H. Zhang, B. Dong, and J.J. Lu Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study BMC Cancer 9 2009 249